Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
We studied the effect of intravenous infusion of synthetic truncated GLP-1 (proglucagon 78-107-amide) on fasting and postprandial gastric acid secretion, gastric emptying, and pancreatic secretion of trypsin and lipase in eight normal volunteers using marker dilution and aspiration technique. The infusion resulted in a plasma concentration of 110 +/- 14 pmol/liter (mean +/- SEM). Truncated GLP-1 significantly inhibited postprandial acid secretion by 43 +/- 11% in spite of unchanged plasma gastrin concentration. Gastric emptying rate decreased significantly; 50% emptying time increased from 16 +/- 2 min to 30 +/- 5 min. Postprandial trypsin and lipase outputs were significantly inhibited by 47 +/- 17% and 40 +/- 9% during truncated GLP-1 infusion. Pancreatic enzyme output was linearly correlated to gastric emptying, and truncated GLP-1 did not affect this relationship, suggesting that the effect on pancreatic secretion was secondary to the effect on gastric emptying. Postprandial insulin and glucagon concentrations were similar with and without truncated GLP-1 infusion in spite of significantly lower blood glucose levels (5.2 +/- 0.2 versus 3.7 +/- 0.3), indicating that GLP-1 stimulated insulin secretion and inhibited glucagon secretion. In conclusion, our results suggest that truncated GLP-1 act as a physiological inhibitor of gastric and pancreatic functions in man.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In particular, GLP-1R agonism not only emerged as a powerful tool in the treatment of T2D and excess adiposity56, but also displayed favorable effects on the cardiovascular system57 and neurodegenerative diseases55.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [57]
In the citing paper
“GLP-1 has been shown to inhibit glucagon secretion and slow gastric emptying.5, 6”
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Physiology of the Gastrointestinal Tract
Ouyang, A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410100162049 · Cited by 950
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationMojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Albano, J. D. M., Ekins, R. P., Maritz, G., & Turner, R. C. (1972) · Acta Endocrinologica · doi:10.1530/acta.0.0700487 · Cited by 620
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615
Self-citationØRSKOV, C., HOLST, J. J., KNUHTSEN, S., BALDISSERA, F. G. A., POULSEN, S. S., & NIELSEN, O. V. (1986) · Endocrinology · doi:10.1210/endo-119-4-1467 · Cited by 482
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Self-citationOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citation
Research works printed but not linked: 4
- Holst JJ: Enteroglucagon. Adv Metab Dis 11:392?419, 1988
- Dimagno EP: Alternations and consequences of interdigestive and poststimulatory human exocrine pancreatic secretion in health and disease. Scand J Gastroenterol 12(suppl 87): 69, 1983
- Holst JJ, Creutzfeldt M, Holm G, Jensen E, Poulsen D, Sparsø B, Schmidt A: Persistent glucagonemia after pancreatectomy in pigs. Diabete Metab 4:75?79, 1978
- Solomon TE: Control of exocrine pancreatic secretion.In Physiology of the Gastrointestinal Tract, 2nd ed. LR Johnson (ed). New York, Raven Press, 1987, pp 1173?1208
Cited by
Items 401–500 of 687
Miholic, J., Hoffmann, M., Holst, J. J., Lenglinger, J., Mittlböck, M., Bergmann, H., & Stacher, G. (2007) · Surgical Endoscopy · doi:10.1007/s00464-005-0804-3 · Cited by 23
Self-citationGlucagon-like peptide 2 inhibits ghrelin secretion in humans
Banasch, M., Bulut, K., Hagemann, D., Schrader, H., Holst, J. J., Schmidt, W. E., & Meier, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.07.009 · Cited by 23
Self-citationYamanouchi, D. (2025) · doi:10.20944/preprints202511.1408.v2 · Cited by 23
Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice
Hammoud, R., Kaur, K. D., Koehler, J. A., Baggio, L. L., Wong, C. K., Advani, K. E., Yusta, B., Efimova, I., Gribble, F. M., Reimann, F., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174825 · Cited by 24
New physiological effects of the incretin hormones GLP-1 and GIP.
Asmar, M. (2011) · PubMed · Cited by 29
Sharma, A., Paliwal, G., Upadhyay, N., & Tiwari, A. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0143-4 · Cited by 28
RetractedJeha, G. S., & Heptulla, R. A. (2006) · Pediatric Diabetes · doi:10.1111/j.1399-543x.2006.00159.x · Cited by 22
Holst, J. J. (2002) · BioDrugs · doi:10.2165/00063030-200216030-00002 · Cited by 24
Self-citationNäslund, E. B., Skogar, S., Efendić, S., & Hellström, P. M. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00054-x · Cited by 25
HOLST, J. J., TOFT-NIELSEN, M.-B., ØRSKOV, C., NAUCK, M., & WILLMS, B. (2006) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb17549.x · Cited by 21
Self-citationKim, K., Kim, K., Shin, M. H., Jang, E. G., Kim, E. Y., Lee, J. H., Ahn, K. S., Um, J., & Jang, H.-J. (2013) · BioChip Journal · doi:10.1007/s13206-013-7213-9 · Cited by 21
GLP-1-mediated gene therapy approaches for diabetes treatment
Tasyurek, H. M., Altunbaş, H., Canatan, H., Griffith, T. S., & Şanlıoğlu, S. (2014) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2014.7 · Cited by 24
Pridal, L., Ingwersen, S. H., Larsen, F. S., Holst, J. J., Adelhorst, K., & Kirk, O. (1995) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/0731-7085(95)01312-9 · Cited by 23
Self-citationDulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers
Anderson, J. E., Thieu, V. T., Boye, K. S., Hietpas, R. T., & García‐Pérez, L. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1218260 · Cited by 23
GLP1 and GIP are involved in the action of synbiotics in broiler chickens
Kolodziejski, P. A., Sassek, M., Chalupka, D., Leciejewska, N., Nogowski, L., Maćkowiak, P., Józefiak, D., Stadnicka, K., Siwek, M. Z., Bednarczyk, M. F., et al. (2018) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-017-0227-8 · Cited by 25
Expression and purification of exendin-4, a GLP-1 receptor agonist, in Escherichia coli
Yin, X., Wei, D., Yi, L., Tao, X., & Ma, Y. (2005) · Protein Expression and Purification · doi:10.1016/j.pep.2004.10.014 · Cited by 21
Hedetoft, C., Sheikh, S. P., Larsen, S. U., & Holst, J. J. (2000) · Pancreas · doi:10.1097/00006676-200001000-00004 · Cited by 21
Self-citationCirculating glucagon-like peptide-1 increases in response to short-term overfeeding in men
Wadden, D., Cahill, F., Amini, P., Randell, E. W., Vasdev, S., Yi, Y., Church, J. G., & Sun, G. (2013) · Nutrition & Metabolism · doi:10.1186/1743-7075-10-33 · Cited by 23
Tolessa, T., Näslund, E. B., & Hellström, P. M. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00220-2 · Cited by 24
Lee, Y., Kwon, M. K., Kang, E. S., Park, Y. M., Choi, S. H., Ahn, C. W., Kim, K., Park, C. W., Soo, B., Kim, S. W., et al. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1153 · Cited by 20
The GLP‐1 system as a therapeutic target
Edwards, M. C. B. (2005) · Annals of Medicine · doi:10.1080/07853890510037400 · Cited by 19
Vlaeminck, N., de Putte, P. B. C. V., Dekeyser, M., Baert, N., Wallyn, A., Vernieuwe, L., Smitz, C. J., Wouters, K., Cauwenberghe, J. V., & Saldien, V. (2026) · Anaesthesia · doi:10.1111/anae.70129 · Cited by 23
Muangchan, N., Khiewvan, B., Chatree, S., Pongwattanapakin, K., Kunlaket, N., Dokmai, T., & Chaikomin, R. (2021) · British Journal Of Nutrition · doi:10.1017/s0007114521003494 · Cited by 25
Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment
Deng, W.-Y., Zhao, Z., Zou, T., Kuang, T.-D., & Wang, J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s421527 · Cited by 22
Lodefalk, M., Carlsson‐Skwirut, C., Holst, J. J., Åman, J., & Bang, P. (2010) · Hormone Research in Paediatrics · doi:10.1159/000308168 · Cited by 22
Self-citationPlamboeck, A., Holst, J. J., Carr, R. D., & Deacon, C. F. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-47920-6_36 · Cited by 22
Self-citationCentral, but not peripheral, glucagon-like peptide-1 inhibits crop emptying in chicks
Tachibana, T., Matsumoto, M., Furuse, M., Hasegawa, S., Yoshizawa, F., & Sugahara, K. (2003) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/s1095-6433(03)00009-6 · Cited by 20
Kong, M., King, P., Macdonald, I. A., Blackshaw, P. E., Perkins, A. C., Armstrong, E., Buchanan, K. D., & Tattersall, R. B. (1998) · Diabetologia · doi:10.1007/s001250050932 · Cited by 19
Evolution of the glucagon-like system across fish
Cardoso, J. C. R., Félix, R. C., da Costa, C. K., Palma, P. S., Canário, A. V. M., & Power, D. M. (2017) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2017.10.003 · Cited by 17
Wang, Y., Wang, J., Gong, Q., Wu, H., Yang, S., He, J., Hu, X., & Huang, T. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0384 · Cited by 18
Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives
Stephens, J., & Edavalath, M. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s6358 · Cited by 17
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Self-citationWatkins, J. D., Carter, S., Atkinson, G., Koumanov, F., Betts, J. A., Holst, J. J., & Gonzalez, J. T. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155375 · Cited by 23
Self-citationIdorn, T., Knop, F. K., Jørgensen, M. B., Holst, J. J., Hornum, M., & Feldt‐Rasmussen, B. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft353 · Cited by 19
Self-citationGLP-1 mimetic drugs and the risk of exocrine pancreatic disease: Cell and animal studies
Williams, J. A. (2015) · Pancreatology · doi:10.1016/j.pan.2015.11.008 · Cited by 18
Bremholm, L., Andersen, U. B., Hornum, M., Hilsted, L., Veedfald, S., Hartmann, B., & Holst, J. J. (2017) · Physiological Reports · doi:10.14814/phy2.13102 · Cited by 20
Self-citationJanumet™: a combination product suitable for use in patients with Type 2 diabetes
Reynolds, J. K., Neumiller, J. J., & Campbell, R. K. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1559 · Cited by 18
NK cells vs. obesity: A tale of dysfunction & redemption
Barra, C. D., O'Shea, D. B., & Hogan, A. E. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109744 · Cited by 20
Sumida, Y., Yoneda, M., Toyoda, H., Yasuda, S., Tada, T., Hayashi, H., Nishigaki, Y., Suzuki, Y., Naiki, T., Morishita, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144939 · Cited by 16
Dipeptidyl peptidase IV(DPP IV): a novel emerging target for the treatment of type 2 diabetes
Wu, J. Q., Chen, Y., Shi, X., & Gu, W. (2009) · 南京医科大学学报:英文版 · doi:10.1016/s1007-4376(09)60061-7 · Cited by 17
Matsuyama‐Yokono, A., Tahara, A., Nakano, R., Someya, Y., Nagase, I., Hayakawa, M., & Shibasaki, M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.03.021 · Cited by 16
Genetic variation inGlp1rexpression influences the rate of gastric emptying in mice
Kumar, K. G., Byerley, L. O., Vólaufová, J., Drucker, D. J., Churchill, G. A., Li, R., York, B., Zuberi, A. R., & Richards, B. K. S. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00640.2007 · Cited by 17
Larsen, M. O., Rolin, B., Ribel, U., Wilken, M., Deacon, C. F., Svendsen, O., Gotfredsen, C. F., & Carr, R. D. (2003) · Journal of Diabetes Research · doi:10.1155/edr.2003.93 · Cited by 21
Neutron activation analysis challenges: Problems and applications in biomedical and other areas
Spyrou, N. M. (1999) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/bf02349533 · Cited by 16
Incretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Jensen, M. N., Israelsen, I. M. E., Wardman, J. H., Jensen, D. B., Andersen, D. B., Toft‐Bertelsen, T. L., Rath, M. F., Holst, J. J., ROSENKILDE, M. M., & MacAulay, N. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00652-x · Cited by 18
Self-citationLu, Z., du Sert, N. P., Chan, S. W., Yeung, C. K., Lin, G., Yew, D. T. W., Andrews, P. L. R., & Rudd, J. A. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0327-6 · Cited by 16
Yau, A. M. W., McLaughlin, J. T., Maughan, R. J., Gilmore, W., & Evans, G. H. (2017) · Nutrients · doi:10.3390/nu9030258 · Cited by 15
Yau, A. M. W., McLaughlin, J. T., Maughan, R. J., Gilmore, W., Ashworth, J., & Evans, G. H. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01331 · Cited by 20
Husník, R., Gaschen, F. P., Fletcher, J. M., & Gaschen, L. E. (2020) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15787 · Cited by 19
Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes
Nagai, Y., Hashimoto, E., Oikawa, R., Asai, S., Terashima, Y., Nakamura, Y., Sasaki, Y., Tsukiyama, H., Fukuda, H., Ohshige, T., et al. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12247 · Cited by 15
E. Näslund, J. B. (2001) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520121133 · Cited by 15
Roges, O. A., Baron, M., & Philis‐Tsimikas, A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.705 · Cited by 15
Histological analysis of glucagon-like peptide-1 receptor expression in chicken pancreas
Watanabe, T., Nishimura, K., Hosaka, Y. Z., Shimosato, T., Yonekura, S., Suzuki, D., Takemoto, C., Monir, M. M., & Hiramatsu, K. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1836-6 · Cited by 15
Discovery of the GI Effects of GLP-1: An Historical Perspective
Holst, J. J. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07519-3 · Cited by 15
Self-citationRole of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare, K. J. (2010) · PubMed · Cited by 18
Treatment of diabetes with glucagon-like peptide-1 gene therapy
Riedel, M. J., & Kieffer, T. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532786 · Cited by 13
Nakamaru, Y., Hayashi, Y., Sekine, M., Kinoshita, S., Thompson, J., Kawaguchi, A., Davies, M., Heuer, H. J., Yamazaki, H., & Akimoto, K. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.03.002 · Cited by 13
Keane, F. M., Chowdhury, S., Yao, T.-W., Nadvi, N. A., Gall, M. G., Chen, Y., Osborne, B., de Ribeiro, A. J. V., Church, W. B., McCaughan, G. W., et al. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/9781849733151-00118 · Cited by 13
Lundgren, J. R., Færch, K., Witte, D. R., Jonsson, A. E., Pedersen, O. B., Hansen, T. F., Lauritzen, T., Holst, J. J., Vistisen, D., Jørgensen, M. E., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0937-7 · Cited by 14
Self-citationGut peptide hormones: Importance for food intake
Näslund, E. B., Schmidt, P. T., & Hellström, P. M. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410010634 · Cited by 13
Nakamaru, Y., Hayashi, Y., Davies, M., Heuer, H. J., Hisanaga, N., & Akimoto, K. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.06.012 · Cited by 14
Surgery for Diabetes: Clinical and Mechanistic Aspects
Kapeluto, J., Tchernof, A., & Biertho, L. D. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.05.008 · Cited by 18
[2-Sulfo-9-fluorenylmethoxycarbonyl]3–exendin-4—a long-acting glucose-lowering prodrug
Shechter, Y., Tsubery, H., & Fridkin, M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00715-0 · Cited by 13
Population pharmacokinetic of paracetamol and atorvastatin with co‐administration of semaglutide
Langeskov, E. K., & Kristensen, K. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.962 · Cited by 12
Camacho, R. C., You, S.-H., D’Aquino, K. E., Li, W., Wang, Y., Gunnet, J. W., Littrell, J. B., Qi, J. S., Kang, L., Jian, W., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1794687 · Cited by 13
Xu, B., Yan, X., Shao, Y., Shen, Q., Hua, R., Ding, R., & Yao, Q. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1835-z · Cited by 12
Gut hormone activity of children born to women with and without gestational diabetes
Chandler-Laney, P. C., Bush, N. C., Rouse, D. J., Mancuso, M., & Gower, B. A. (2013) · Pediatric Obesity · doi:10.1111/j.2047-6310.2012.00140.x · Cited by 12
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Lamos, E. M., Kristan, M. M., Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1917374 · Cited by 12
The Enteroendocrine System in Obesity
Miedzybrodzka, E. L., Reimann, F., & Gribble, F. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_582 · Cited by 12
6 Gut hormones and intestinal function
Holst, J. J., & Schmidt, P. (1994) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80229-0 · Cited by 12
Self-citationGlucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Viljoen, A., & Bain, S. C. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1642 · Cited by 11
A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
Samms, R. J., & Kusminski, C. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105443 · Cited by 12
Gastric inhibitory polypeptide is the major insulinotropic factor in K(ATP) null mice
Tsukiyama, K., Yamada, Y., Miyawaki, K., Hamasaki, A., Nagashima, K., Hosokawa, M., Fujimoto, S., Takahashi, A., Toyoda, K., Toyokuni, S., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510407 · Cited by 11
Chen, J., Bai, G., Yang‐Hartwich, Y., Geng, P., Cao, Y., & Zhu, Y. (2006) · Peptides · doi:10.1016/j.peptides.2006.12.012 · Cited by 13
Hatew, B., Inabu, Y., Sugino, T., & Steele, M. A. (2019) · Journal of Dairy Science · doi:10.3168/jds.2018-15578 · Cited by 14
In vitro cell cultures of Brunner’s glands from male mouse to study GLP-1 receptor function
Voetmann, L. M., Underwood, C. R., Rolin, B., Hansen, A. K., Kirk, R. K., Pyke, C., Knudsen, L. B., & Frederiksen, K. S. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00345.2021 · Cited by 10
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes
Stein, S. A., Lamos, E. M., & Davis, S. N. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.889683 · Cited by 10
Ardehali, H. (2024) · Journal of Clinical Investigation · doi:10.1172/jci186225 · Cited by 9
Wu, M., Li, Q., Zhang, H., Zhu, X., Li, X., Li, Y., Sun, H., & Ding, Y. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.895 · Cited by 11
Fujiwara, Y., Yamane, S., Harada, N., Ikeguchi, E., Usui, R., Nakamura, T., Iwasaki, K., Suzuki, K., Yabe, D., Hayashi, Y., et al. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00312.2020 · Cited by 9
Emerging role of insulin with incretin therapies for management of type 2 diabetes
Ahluwalia, R., & Vora, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0005-0 · Cited by 12
Acute satiety response of mammalian, avian and fish proteins in dogs
Boler, B. M. V., Faber, T. A., Bauer, L. L., Swanson, K. S., Smiley, S., Bechtel, P. J., & Fahey, G. C., Jr. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511002261 · Cited by 13
Incretin manipulation in diabetes management
Pappachan, J. M., Raveendran, A. V., & Sriraman, R. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.774 · Cited by 10
Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
Reynolds, J. (2009) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s4637 · Cited by 9
Action of GLP-1 (7-36) amide and exendin-4 on Suncus murinus (house musk shrew) isolated ileum
Chan, S. W., He, J., Lin, G., Rudd, J. A., & Yamamoto, K. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.03.050 · Cited by 9
Glycemic response in healthy rats fed with composite cereal bars
Utrilla‐Coello, R. G., Agama‐Acevedo, E., Osorio‐Díaz, P., Reynoso‐Camacho, R., & Bello‐Pérez, L. A. (2012) · Starch - Stärke · doi:10.1002/star.201200129 · Cited by 9
Glucagon-like peptide 1 (GLP-1) and incretin mimetics for the treatment of diabetes
Nauck, M. A. (2005) · Practical Diabetes · doi:10.1002/pdi.801 · Cited by 8
Meier, J. J., Nauck, M. A., Kask, B., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Gallwitz, B. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i12.1874 · Cited by 8
Structure and Function of the Glucagon-Like Peptide-1 Receptor
Thorens, B., & Widmann, C. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-61150-6_16 · Cited by 9
Mooney, M. H., Abdel‐Wahab, Y. H. A., McKillop, A. M., O'Harte, F. P. M., & Flatt, P. R. (2002) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(01)00237-9 · Cited by 8
Dupre, J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2005.06.012 · Cited by 8
Absorption of glucagon-like peptide-1 can be protracted by zinc or protamine
Pridal, L., Agerbæk, H., Christensen, L. N., Thomsen, K., & Kirk, O. (1996) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(95)04480-9 · Cited by 8
Incretin-Based Therapy for Type 2 Diabetes Mellitus: Pancreatic and Extrapancreatic Effects
Hartman, I., Rojas, E., & Rodríguez-Molina, D. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f27d · Cited by 8
Uhles, S., Wang, H., Benardeau, A. M., Prummer, M., Brecheisen, M., Sewing, S., Tobalina, L., Bosco, D., Wollheim, C. B., Migliorini, C., et al. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01352.x · Cited by 7
Zhao, L., Liao, F., Wang, C., Chen, M., Wei, A., Du, S., Ma, B., Hu, X., Wu, Z., Wang, R., et al. (2009) · 中国科学通报:英文版 · doi:10.1007/s11434-009-0699-9 · Cited by 6
Haselmann, K. F., Nielsen, P. F., & Zubarev, R. A. (2005) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2005.01.009 · Cited by 7
Chaikomin, R., Jones, K. L., Feinle‐Bisset, C., Meyer, J. H., Horowitz, M., & Rayner, C. K. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283200073 · Cited by 8
Alcaino, C., Reimann, F., & Gribble, F. M. (2024) · The Journal of Physiology · doi:10.1113/jp286293 · Cited by 10
Metadata
- Authors
- Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Digestive Diseases and Sciences
- Published
- 1993-04
- Volume
- 38
- Issue
- 4
- Pages
- 665-673
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2087063469
- Cited by
- 670
- References
- 39
- Citations by year
- 2026: 12 · 2025: 10 · 2024: 20 · 2023: 9 · 2022: 14 · 2021: 22 · 2020: 10 · 2019: 19 · 2018: 17 · 2017: 18 · 2016: 23 · 2015: 27 · 2014: 25 · 2013: 21 · 2012: 25
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- gastric acid secretion, gastric emptying, postprandial insulin secretion, glucagon secretion, blood glucose, gastrin, incretins
- MeSH terms
- Adult, Depression, Chemical, Female, Gastric Acid, Gastric Emptying, Gastric Mucosa, Glucagon, Humans, Infusions, Intravenous, Lipase, Male, Pancreas, Peptide Fragments, Protein Precursors, Random Allocation, Reference Values, Time Factors, Trypsin, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.